Patents by Inventor Ponciano CRUZ

Ponciano CRUZ has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-DC-HIL antibodies for cancer diagnosis, prognosis and therapy
    Patent number: 11648307
    Abstract: The present disclosure is directed to antibodies that bind to DC-HIL on the surface of myeloid-derived suppressor cells, and thus antagonize the T cell suppressor function of these cells, as well as their use in diagnosing and treating cancers such as melanoma.
    Type: Grant
    Filed: December 31, 2019
    Date of Patent: May 16, 2023
    Assignee: The Board of Regents of The University of Texas System
    Inventors: Kiyoshi Ariizumi, Ponciano Cruz
  • ANTI-DC-HIL ANTIBODIES FOR CANCER DIAGNOSIS, PROGNOSIS AND THERAPY
    Publication number: 20200206343
    Abstract: The present disclosure is directed to antibodies that bind to DC-HIL on the surface of myeloid-derived suppressor cells, and thus antagonize the T cell suppressor function of these cells, as well as their use in diagnosing and treating cancers such as melanoma.
    Type: Application
    Filed: December 31, 2019
    Publication date: July 2, 2020
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Kiyoshi ARIIZUMI, Ponciano CRUZ
  • Anti-DC-HIL antibodies for cancer diagnosis, prognosis and therapy
    Patent number: 10517948
    Abstract: The present disclosure is directed to antibodies that bind to DC-HIL on the surface of myeloid-derived suppressor cells, and thus antagonize the T cell suppressor function of these cells, as well as their use in diagnosing and treating cancers such as melanoma.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: December 31, 2019
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Kiyoshi Ariizumi, Ponciano Cruz
  • ANTI-DC-HIL ANTIBODIES FOR CANCER DIAGNOSIS, PROGNOSIS AND THERAPY
    Publication number: 20180064809
    Abstract: The present disclosure is directed to antibodies that bind to DC-HIL on the surface of myeloid-derived suppressor cells, and thus antagonize the T cell suppressor function of these cells, as well as their use in diagnosing and treating cancers such as melanoma.
    Type: Application
    Filed: March 9, 2016
    Publication date: March 8, 2018
    Inventors: Kiyoshi ARIIZUMI, Ponciano CRUZ